WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the ...
GSK said that both the Anchor-1 and Anchor-2 trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score after 52 weeks, as well as a change in mean nasal ...
LONDON, UK I October 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, ...
The stock options were granted to the new employees on their respective hire dates (October 7, 2024, and October 14, 2024) with an exercise price equal to the closing price of the company’s common ...
Cerebral venous sinus thrombosis (CVST ... Symptoms include nausea, seizures, severe focal neurological deficits, coma, and headache (the most common presenting symptom). Anticoagulation is ...
Seek emergency care if your symptoms include eye swelling, vision changes, severe headache, neck stiffness, or fever. Nasal congestion occurs when tissue lining the nose swells because of inflamed ...